menu

JAK Inhibitor Therapy for Alopecia Areata: Expert Guidance to Fill in the Gaps

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

JAK Inhibitor Therapy for Alopecia Areata: Expert Guidance to Fill in the Gaps

1.00 credits
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    The treatment landscape for alopecia areata is shifting with the recent FDA approval of 2 JAK inhibitors and a robust development pipeline. Tune in to this CME-certified, on-demand activity for the latest insights about pathophysiology, diagnosis, management, and much more from renowned dermatology experts. 

  • Disclosure of Conflicts of Interest

    Brittany Craiglow, MD: consultant/advisor/speaker: AbbVie, Concert Pharmaceuticals, Incyte, Lilly, Pfizer, Regeneron, Sanofi-Genzyme.

    Maryanne Makredes Senna, MD, FAAD: consultant/advisor/speaker: AbbVie, Eli Lilly, Kintor, L’Oréal, Pfizer.

  • Target Audience

    The intended target audience for this program is US dermatologists and NP/PAs who treat patients with AA.

  • Learning Objectives

    Formulate an accurate diagnosis and classification of AA based on multiple disease and patient factors

    • Detail factors that may predict a patient’s positive or negative response to JAK inhibitor therapy for AA
    • Evaluate patients with AA for treatment candidacy with JAK inhibitor therapy
  • Goal Statement

    The goal of this program is to improve the knowledge, competence, and performance of HCPs prescribing mycophenolate treatment for female patients of reproductive potential.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the National Alopecia Areata Foundation. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1  AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

    Physician Associate Continuing Medical Education
    Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 09, 2024. PAs should only claim commensurate with the extent of their participation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)


    Provided by Clinical Care Options, LLC in partnership with the National Alopecia Areata Foundation.

  • Commercial Support

    This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

  • Disclosure of Unlabeled Use:

    The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The treatment landscape for alopecia areata is shifting with the recent FDA approval of 2 JAK inhibitors and a robust development pipeline. Tune in to this CME-certified, on-demand activity for the latest insights about pathophysiology, diagnosis, management, and much more from renowned dermatology experts. 

  • Disclosure of Conflicts of Interest

    Brittany Craiglow, MD: consultant/advisor/speaker: AbbVie, Concert Pharmaceuticals, Incyte, Lilly, Pfizer, Regeneron, Sanofi-Genzyme.

    Maryanne Makredes Senna, MD, FAAD: consultant/advisor/speaker: AbbVie, Eli Lilly, Kintor, L’Oréal, Pfizer.

  • Target Audience

    The intended target audience for this program is US dermatologists and NP/PAs who treat patients with AA.

  • Learning Objectives

    Formulate an accurate diagnosis and classification of AA based on multiple disease and patient factors

    • Detail factors that may predict a patient’s positive or negative response to JAK inhibitor therapy for AA
    • Evaluate patients with AA for treatment candidacy with JAK inhibitor therapy
  • Goal Statement

    The goal of this program is to improve the knowledge, competence, and performance of HCPs prescribing mycophenolate treatment for female patients of reproductive potential.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the National Alopecia Areata Foundation. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1  AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

    Physician Associate Continuing Medical Education
    Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 09, 2024. PAs should only claim commensurate with the extent of their participation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)


    Provided by Clinical Care Options, LLC in partnership with the National Alopecia Areata Foundation.

  • Commercial Support

    This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

  • Disclosure of Unlabeled Use:

    The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule30 May 2024